Cryptococcosis Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cryptococcosis Therapeutics Market Analysis
Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection.
Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia) etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining.
According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths. Therefore with the growing prevalence of cryptococcosis and availability of advance treatment are the key factors that drives the growth of cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.
Cryptococcosis Therapeutics Market Trends
This section covers the major market trends shaping the Cryptococcosis Therapeutics Market according to our research experts:
Flucytosine Segment is Expected to Hold a Significant Market Share
Flucytosine is a small, water-soluble molecule which is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications. Flucytosine was major revenue holding segment because it is given as first-line treatment in combination with other antifungal medications.
According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. The increasing prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors for the growth of the cryptococcosis market.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major share globally in cryptococcosis market due to the rising prevalence of cryptococcosis, the rise in technological advancements, and higher cost of medication in this region.
As per the study article published by National Institute of Health in 2019, in the United States prevalence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. Therefore, North America holds a major market share due to the rising prevalence of cryptococcosis in the endemic areas that are fueling the growth of the overall regional market to a large extent.
Cryptococcosis Therapeutics Industry Overview
The Cryptococcosis Therapeutics Market is moderately consolidated and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some companies are adopting numerous strategies including acquisitions and collaborations to sustain market competition.
Cryptococcosis Therapeutics Market Leaders
-
Bristol-Myers Squibb Company
-
Pfizer Inc
-
Astellas Pharma Inc.
-
Sigmapharm Laboratories LLC
-
Glenmark Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Cryptococcosis Therapeutics Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Growing Prevalence of Fatal Fungal Disease
-
4.2.2 Favourable Reimbursement Policies
-
4.2.3 New and Advanced Treatment Opportunities
-
-
4.3 Market Restraints
-
4.3.1 Adverse Effects of the Treatment
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Treatment
-
5.1.1 Amphotericin B
-
5.1.2 Flucytosine
-
5.1.3 Fluconazole
-
5.1.4 Others
-
-
5.2 Geography
-
5.2.1 North America
-
5.2.1.1 United States
-
5.2.1.2 Canada
-
5.2.1.3 Mexico
-
-
5.2.2 Europe
-
5.2.2.1 Germany
-
5.2.2.2 United Kingdom
-
5.2.2.3 France
-
5.2.2.4 Italy
-
5.2.2.5 Spain
-
5.2.2.6 Rest of Europe
-
-
5.2.3 Asia-Pacific
-
5.2.3.1 China
-
5.2.3.2 Japan
-
5.2.3.3 India
-
5.2.3.4 Australia
-
5.2.3.5 South Korea
-
5.2.3.6 Rest of Asia-Pacific
-
-
5.2.4 Middle-East and Africa
-
5.2.4.1 GCC
-
5.2.4.2 South Africa
-
5.2.4.3 Rest of Middle-East and Africa
-
-
5.2.5 South America
-
5.2.5.1 Brazil
-
5.2.5.2 Argentina
-
5.2.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Astellas Pharma Inc
-
6.1.2 Bristol-Myers Squibb Company
-
6.1.3 Glenmark Pharmaceuticals
-
6.1.4 Janssen Biotech Inc. (Johnson & Johnson)
-
6.1.5 Novartis AG
-
6.1.6 Pfizer Inc.
-
6.1.7 Sigmapharm Laboratories LLC
-
6.1.8 Valeant Pharmaceuticals Inc.
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cryptococcosis Therapeutics Industry Segmentation
As per the scope of the report, cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. Cryptococcosis infect humans and animals, usually by inhalation of the fungus, which results in lung infection that may spread to the brain, causing meningoencephalitis.
| By Treatment | |
| Amphotericin B | |
| Flucytosine | |
| Fluconazole | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cryptococcosis Therapeutics Market Research FAQs
What is the current Cryptococcosis Therapeutics Market size?
The Cryptococcosis Therapeutics Market is projected to register a CAGR of 4.70% during the forecast period (2024-2029)
Who are the key players in Cryptococcosis Therapeutics Market?
Bristol-Myers Squibb Company, Pfizer Inc, Astellas Pharma Inc., Sigmapharm Laboratories LLC and Glenmark Pharmaceuticals are the major companies operating in the Cryptococcosis Therapeutics Market.
Which is the fastest growing region in Cryptococcosis Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cryptococcosis Therapeutics Market?
In 2024, the North America accounts for the largest market share in Cryptococcosis Therapeutics Market.
What years does this Cryptococcosis Therapeutics Market cover?
The report covers the Cryptococcosis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Cryptococcosis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cryptococcosis Therapeutics Industry Report
Statistics for the 2024 Cryptococcosis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cryptococcosis Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Cryptococcosis Therapeutics Report Snapshots
